Kawasaki disease
Conditions
Interventions
Until day 8 of illness, imfliximab 5mg/kg (over 1years-old) Until day 9 , continuos infusion of cyclosporin A (2.5-3.0mg/kg/day).
Sponsors
Dokkyo medical university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Children (under 15 years-old) with Kawasaki disease at acute phase until day 8 of illness, including incomplete Kawasaki disease. All patients or their parents were informed of the significance and risks of the study and gave their consent according to the rules of our university hospital.
Exclusion criteria
Exclusion criteria: shock or oversensitivity of asprin, immunoglobulin, infliximab, and cyclosporin A. low contraction at left ventricle (FS<0.28) low renal function (creatinine <0.9mg/dl or estimated GFR<50ml/min/1.73m2) Contraindication of infliximab and cyclosporin A. Liver dysfunction (AST or ALT >500 U/L) before continuos infusion of cyclosporin A. Critical active bacterial infection before therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of coronary artery dilatation until 1 month. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of side effect with combined therapy. Evaluation of alternation of expression levels of RNA. | — |
Countries
Japan
Contacts
Public ContactIRB IRB
Dokkyo medical university Department of pediatrics
Outcome results
None listed